Niagen Bioscience Q2 sales beat estimates

Niagen Bioscience

06/08/2025 21:18

Overview

Niagen Bioscience Q2 net sales rise 37% to $31.1 mln, beating estimates, per LSEG data

Net income reaches $3.6 mln, up from breakeven in prior year period

Company raises full-year 2025 revenue growth outlook to 22%-27%

Outlook

Niagen Bioscience raises 2025 revenue growth outlook to 22%-27%

Company expects slight improvement in gross margin year-over-year

Sales and marketing expenses to rise, but decrease as percentage of sales

General and administrative expenses to increase by $7.0 to $8.0 mln

Result Drivers

TRU NIAGEN SALES - Sales reached $22.7 mln, growing 22%, driven by strong e-commerce performance

NIAGEN INGREDIENT SALES - Increased 135% to $7.4 mln, including food-grade and pharmaceutical-grade sales

GROSS MARGIN IMPROVEMENT - Increased 480 basis points to 65.0% due to changes in product and business mix

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$31.12 mln
$28.30 mln (5 Analysts)
Q2 Net Income
$3.61 mln
Q2 Gross Profit
$20.23 mln
Q2 Operating Expenses
$17.04 mln
Q2 Operating Income
$3.18 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Niagen Bioscience Inc is $16.00, about 42.8% above its August 5 closing price of $9.16

The stock recently traded at 48 times the next 12-month earnings vs. a P/E of 55 three months ago

Press Release: ID:nBw98DdxXa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)